ArticleThe oncologist2022

Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.

Richard S Finn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.